Magle Group’s vascular embolic product Embocept® S receives regulatory approval in Argentina
Magle Chemoswed Holding Reports Financial Results For Third Quarter 2022
Invitation to presentation of Magle Group’s report for Q3 2022
Magle Chemoswed Holding AB announces change of Certified Adviser to Vator Securities
Magle Group appoints new Chief Marketing and Innovation Officer
Magle Chemoswed Holding Reports Financial Results For First Half year 2022
Magle Chemoswed Holding AB announces the resignation of Julia Kamber Rouhi from the Board of Directors of Magle Chemoswed Holding.
Invitation to presentation of Magle Chemoswed’s report for Q2 2022
First patients enrolled in a post-market study of Magle Group’s innovative medical device SmartPAN®
Magle Group announces innovation sponsorship with leading life science incubator in Sweden

Magle Chemoswed AB

Agneslundsvägen 27
212 15 Malmö, Sweden
info@maglechemoswed.com
+46 (0)40 38 33 00

Magle Chemoswed and Logos are registered trademarks of Magle Chemoswed.